Origio A/S – Trademark Portfolio
Entity Type: 03
Origio A/S holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 5 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include BLASTGEN and VITRIGUARD. The owner is based in Måløv.
Knardrupvej 2
Måløv DK2760 , DK
Showing of trademarks Trademarks
Trademark Classifications
Origio A/S's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does Origio A/S have?
Origio A/S has 8 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 3 cancelled.
What trademark classes does Origio A/S file in?
Origio A/S files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Origio A/S's most well-known trademarks?
Origio A/S's registered trademark portfolio includes well-known marks such as BLASTGEN and VITRIGUARD. These are among 2 currently registered trademarks in the portfolio.
What is Origio A/S's trademark registration success rate?
Origio A/S has a 33% trademark registration rate, with 2 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.